Goldline Pharmaceutical Limited raises Rs 11.61 crore and repays debt

Goldline Pharmaceutical Limited reported Rs 11.61 crore of combined proceeds from share capital and securities premium in the half year ended September 30, 2026, while repaying Rs 8.50 crore of long- and short-term borrowings. Goldline Pharmaceutical’s financing cash flow was an inflow of Rs 86.01 lakh, and cash and cash equivalents rose to Rs 1.56 crore.

How did Goldline Pharmaceutical fund itself in the September 2026 half year?

Goldline Pharmaceutical funded its reported financing activity through Rs 2.70 crore of share-capital proceeds and Rs 8.91 crore of securities-premium proceeds in the half year ended September 30, 2026. The two cash-flow items totalled Rs 11.61 crore before the company recorded Rs 1.76 crore of share-issue expenses and Rs 21.68 lakh of dividend paid during the period.

Goldline Pharmaceutical reported net cash generated from financing activities of Rs 86.01 lakh for the September 2026 half year, compared with a net financing outflow of Rs 3.40 crore for the year ended March 31, 2026. The periods are not directly comparable because the latest figures cover six months and the earlier figures cover a full year, but the September-period equity-related proceeds offset reported debt repayments, finance cost of Rs 27.92 lakh and issue expenses.

The balance sheet recorded shareholders’ funds of Rs 25.94 crore at September 30, 2026, up from Rs 14.25 crore at March 31, 2026. Share capital rose by Rs 2.70 crore to Rs 11.41 crore, while reserves and surplus increased to Rs 14.53 crore from Rs 5.54 crore; the filing does not disclose the issue price, number of shares or other terms of the transactions.

Which borrowings did Goldline Pharmaceutical repay?

Goldline Pharmaceutical reported net repayment of Rs 79.66 lakh in long-term borrowings and Rs 7.70 crore in short-term borrowings in its September 2026 half-year cash-flow statement. The combined repayment was Rs 8.50 crore, compared with Rs 1.87 crore of combined long- and short-term repayment reported for the year ended March 31, 2026.

Goldline Pharmaceutical’s long-term borrowings stood at Rs 66.65 lakh on September 30, 2026, down from Rs 1.46 crore on March 31, 2026 and Rs 3.51 crore on September 30, 2025. The balance sheet does not show a separate short-term borrowing balance at September 30, 2026, whereas the comparable September 2025 balance was Rs 6.60 crore.

The company’s total non-current liabilities were Rs 1.79 crore at September 30, 2026, compared with Rs 2.51 crore at March 31, 2026. Other long-term liabilities remained Rs 22 lakh across the two dates, while long-term provisions rose to Rs 90.38 lakh from Rs 82.45 lakh, showing that the change in non-current liabilities included lower long-term borrowings alongside higher provisions.

What happened to Goldline Pharmaceutical’s cash and working capital?

Goldline Pharmaceutical ended the September 2026 half year with cash and cash equivalents of Rs 1.56 crore, an increase of Rs 96.28 lakh from Rs 59.24 lakh at the beginning of the period. Operating activities contributed Rs 10.93 lakh, investing activities used Rs 66,000 and financing activities added Rs 86.01 lakh.

Goldline Pharmaceutical generated Rs 2.71 crore of operating cash flow before working-capital changes, compared with profit before extraordinary losses and tax of Rs 2.32 crore. Working capital then absorbed Rs 2.59 crore, leaving cash generated from operations of Rs 11.73 lakh before Rs 80,000 of income-tax payments.

Trade receivables used Rs 2.40 crore of cash during the half year, while other current assets used Rs 60.54 lakh and short-term loans and advances used Rs 44.38 lakh. Inventory generated Rs 22.79 lakh of cash and trade payables contributed Rs 12.90 lakh, but these inflows did not offset the reported receivables and other asset movements.

The period-end balance sheet showed trade receivables of Rs 18.53 crore, up from Rs 16.13 crore at March 31, 2026. Inventories fell to Rs 5.98 crore from Rs 6.21 crore, while short-term loans and advances increased to Rs 2.43 crore from Rs 1.98 crore, providing balance-sheet context for the operating cash-flow movements.

How did Goldline Pharmaceutical’s earnings compare with earlier periods?

Goldline Pharmaceutical reported revenue from operations of Rs 14.93 crore for the half year ended September 30, 2026, compared with Rs 13.89 crore for the half year ended September 30, 2025. Profit after tax rose to Rs 2.05 crore from Rs 1.43 crore, and basic and diluted earnings per share increased to Rs 2.31 from Rs 1.96.

Goldline Pharmaceutical’s profit before tax was Rs 2.32 crore in the September 2026 half year, against Rs 1.85 crore a year earlier. Finance cost was Rs 27.92 lakh, compared with Rs 11.81 lakh in the September 2025 half year, while total expenses were Rs 12.61 crore against Rs 12.04 crore.

The September 2026 revenue was lower than Rs 17.31 crore reported for the half year ended March 31, 2026, and profit after tax was below Rs 2.76 crore for that preceding half year. The company states that it operates in one business, marketing and distribution of pharmaceutical products, and therefore did not provide segment revenue or profit information.

Goldline Pharmaceutical’s September 2026 standalone results were unaudited and were approved by the Board on November 14, 2026. Its statutory auditor issued an unmodified limited-review report dated November 14, 2026, stating that nothing had come to its attention to indicate that the results were not prepared and disclosed as required.

Conclusion

Goldline Pharmaceutical’s September 2026 half-year filing records a funding shift in which Rs 11.61 crore of share-capital and securities-premium proceeds accompanied Rs 8.50 crore of reported debt repayment. Shareholders’ funds increased by Rs 11.69 crore from March 31, 2026, long-term borrowings declined by Rs 79.67 lakh and cash increased by Rs 96.28 lakh, even as working capital absorbed Rs 2.59 crore of operating cash.

The disclosed matter to watch is notification of the Code on Social Security, 2020 and its related rules. Goldline Pharmaceutical says the implementation date has not yet been notified and that it will assess and record the effect on contributions toward employee benefits, including provident fund and gratuity, when the Code and rules are notified.